Sensus Blog

The future of skin cancer treatment is now. Stay ahead of the curve with our library of informational blogs.

April
27
2026

Basal Cell Carcinoma vs. Squamous Cell Carcinoma: What’s the Difference?

Melanoma and non-melanoma are two primary categories of skin cancer. Each presents different symptoms and treatment options. Within the non-melanoma skin cancer – sometimes referred to as NMSC – category, the two most common types…

February
05
2018

Sensus Healthcare Launches Collaboration with BirchBioMed to Treat and Prevent Scarring for Keloids Patients Around the World

BOCA RATON, Fla., Feb. 5, 2018 — Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today Sensus’…

February
01
2018

The Surgeon General’s Call to Action to Prevent Skin Cancer

The Surgeon General has released a Call to Action to address Skin Cancer as a major public health problem. The executive summary includes strategies for prevention with clear and concisely outlined goals. Click the link…

February
01
2018

Sensus Healthcare Reports Record Revenue for 2017 Fourth Quarter and Full Year

Ninth consecutive quarter of double-digit year-over-year revenue growth Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Feb. 1, 2018 — Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in…

January
26
2018

When to Suggest SRT Therapy Over Mohs Surgery

For decades, Mohs surgery has been considered the “gold standard” for the treatment of basal cell carcinomas and squamous cell carcinomas, even for cases where cosmetically important features of the face like the eyes, nose,…

Archives
Archives

IN THE NEWS

CEO Joseph Sardano on Coding for Superficial Radiation Therapy